UBS AM
AVBP icon

UBS AM’s ArriVent BioPharma AVBP Stock Holding History

UBS AM’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
11,357
+350
+3% +$7.91K ﹤0.01% 2679
2025
Q4 		$221K Buy
11,007
+45
+0.4% +$937 ﹤0.01% 2452
2025
Q3 		$202K Sell
10,962
-18,593
-63% -$365K ﹤0.01% 2223
2025
Q2 		$643K Buy
+29,555
New +$614K ﹤0.01% 2463
2025
Q1 		– Sell
-8,165
Closed -$218K – 2707
2024
Q4 		$218K Buy
+8,165
New +$234K ﹤0.01% 2633

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS AM's AVBP Position: Q1 2026 in Review

UBS AM increased its ArriVent BioPharma (AVBP) stake by 3.2% in Q1 2026, buying an estimated $7.91K and bringing the position to 11,357 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

UBS AM first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. The position peaked at $643K in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • UBS AM held 11,357 shares of ArriVent BioPharma worth $262K as of Q1 2026.
  • UBS AM bought 350 ArriVent BioPharma shares in Q1 2026, an estimated $7.91K.
  • ArriVent BioPharma made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2679 holding.
  • UBS AM first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
  • UBS AM's ArriVent BioPharma position peaked at $643K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.